ACT Brief: ICON-Microsoft AI Partnership, DCT Site Burden, and AI-Enabled Neuroimmune Discovery

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• ICON named Microsoft as a preferred technology partner to accelerate Orbis, ICON's agentic AI platform. The partnership combines Microsoft Fabric and Azure infrastructure with domain-specific agents embedded in trial workflows, spanning protocol digitization, site identification, monitoring, and patient engagement.
• In Part 2 of her recent interview with ACT at the 2026 DIA Global Annual Meeting, Joan Chambers, independent senior consultant at Tufts CSDD, examined operational challenges sites face implementing DCT components alongside traditional trial management. The industry remains in a learning phase where data will ultimately need to guide which modalities work best in which contexts.
• Insilico Medicine and SK Biopharmaceuticals entered an R&D collaboration on AI-enabled drug discovery in neuroimmune CNS disorders. Insilico's Pharma.AI platform will generate candidates while SK Biopharmaceuticals handles late-stage development and US commercialization, establishing a scalable platform for future CNS programs.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.